Compare MCRB & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCRB | GLU |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.7M | 119.8M |
| IPO Year | 2015 | N/A |
| Metric | MCRB | GLU |
|---|---|---|
| Price | $8.65 | $21.27 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $14.33 | N/A |
| AVG Volume (30 Days) | ★ 93.5K | 12.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.60% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 2.40 | 0.62 |
| Revenue | ★ $126,325,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $3.43 | $34.47 |
| Revenue Growth | ★ 1672.24 | N/A |
| 52 Week Low | $0.36 | $14.07 |
| 52 Week High | $29.98 | $21.69 |
| Indicator | MCRB | GLU |
|---|---|---|
| Relative Strength Index (RSI) | 26.09 | 75.73 |
| Support Level | $7.12 | $17.78 |
| Resistance Level | $8.49 | $21.69 |
| Average True Range (ATR) | 1.13 | 0.35 |
| MACD | -0.42 | 0.03 |
| Stochastic Oscillator | 5.42 | 87.14 |
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.